In cancer models, synergistic antitumor effects were found with the combination of PD-1/PD-L1 blockade and neutralization of either IL-618 or IL-1β,19 indicating that targeting the inflammatory TME could amplify PD-1 blockade efficacy. This evidence concerns the gene CD274 and cancer.